Real‐World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation

This study aims to measure the plasma levels of rivaroxaban and apixaban among Asian patients with atrial fibrillation and compare the results with expected drug levels from clinical studies. A total of 73 patients taking rivaroxaban and 105 patients taking apixaban were enrolled. Peak and trough le...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2020-01, Vol.107 (1), p.278-286
Main Authors: Lin, Shin‐Yi, Kuo, Ching‐Hua, Yeh, Shin‐Joe, Tsai, Li‐Kai, Liu, Yen‐Bin, Huang, Chih‐Fen, Tang, Sung‐Chun, Jeng, Jiann‐Shing
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aims to measure the plasma levels of rivaroxaban and apixaban among Asian patients with atrial fibrillation and compare the results with expected drug levels from clinical studies. A total of 73 patients taking rivaroxaban and 105 patients taking apixaban were enrolled. Peak and trough levels were measured using ultra‐high performance liquid chromatography with tandem mass spectrometry. The percentage of those with drug levels within the expected range reported in clinical studies was significantly higher in the apixaban group than in the rivaroxaban group, both for trough (84.8% vs. 64.4%; P = 0.002) and peak levels (76.9% vs. 33.8%; P 
ISSN:0009-9236
1532-6535
DOI:10.1002/cpt.1601